Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-blind, Vehicle-controlled, Multicenter Phase III Study to Evaluate the Safety,
- Company
- Biofrontera Inc. (BFRI)
- Indication
- Actinic Keratoses
Other upcoming events for BFRI
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.